PMID- 23454528
OWN - NLM
STAT- MEDLINE
DCOM- 20131126
LR  - 20191210
IS  - 1873-7064 (Electronic)
IS  - 0028-3908 (Linking)
VI  - 70
DP  - 2013 Jul
TI  - Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, 
      scopolamine or Abeta(1)(-)(4)(2) in mice novel object and object location recognition tasks.
PG  - 261-7
LID - S0028-3908(13)00044-0 [pii]
LID - 10.1016/j.neuropharm.2013.02.002 [doi]
AB  - Neuropeptide S (NPS), the endogenous ligand of NPSR, has been shown to promote 
      arousal and anxiolytic-like effects. According to the predominant distribution of 
      NPSR in brain tissues associated with learning and memory, NPS has been reported 
      to modulate cognitive function in rodents. Here, we investigated the role of NPS 
      in memory formation, and determined whether NPS could mitigate memory impairment 
      induced by selective N-methyl-D-aspartate receptor antagonist MK801, muscarinic 
      cholinergic receptor antagonist scopolamine or Abeta(1)(-)(4)(2) in mice, using novel object 
      and object location recognition tasks. Intracerebroventricular (i.c.v.) injection 
      of 1 nmol NPS 5 min after training not only facilitated object recognition memory 
      formation, but also prolonged memory retention in both tasks. The improvement of 
      object recognition memory induced by NPS could be blocked by the selective NPSR 
      antagonist SHA 68, indicating pharmacological specificity. Then, we found that 
      i.c.v. injection of NPS reversed memory disruption induced by MK801, scopolamine 
      or Abeta(1)(-)(4)(2) in both tasks. In summary, our results indicate that NPS facilitates 
      memory formation and prolongs the retention of memory through activation of the 
      NPSR, and mitigates amnesia induced by blockage of glutamatergic or cholinergic 
      system or by Abeta(1)(-)(4)(2), suggesting that NPS/NPSR system may be a new target for 
      enhancing memory and treating amnesia.
CI  - Copyright (c) 2013 Elsevier Ltd. All rights reserved.
FAU - Han, Ren-Wen
AU  - Han RW
AD  - Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of 
      Biochemistry and Molecular Biology, School of Basic Medical Sciences, Lanzhou 
      University, 222 Tian Shui South Road, Lanzhou 730000, PR China.
FAU - Zhang, Rui-San
AU  - Zhang RS
FAU - Xu, Hong-Jiao
AU  - Xu HJ
FAU - Chang, Min
AU  - Chang M
FAU - Peng, Ya-Li
AU  - Peng YL
FAU - Wang, Rui
AU  - Wang R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130221
PL  - England
TA  - Neuropharmacology
JT  - Neuropharmacology
JID - 0236217
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (Neuropeptides)
RN  - 0 (Peptide Fragments)
RN  - 0 (Receptors, Neuropeptide)
RN  - 0 (amyloid beta-protein (1-42))
RN  - 0 (neuropeptide S receptor, mouse)
RN  - 0 (neuropeptide S, mouse)
RN  - 6LR8C1B66Q (Dizocilpine Maleate)
RN  - DL48G20X8X (Scopolamine)
SB  - IM
MH  - Amyloid beta-Peptides/administration & dosage/*antagonists & 
      inhibitors/pharmacology
MH  - Animals
MH  - Dizocilpine Maleate/administration & dosage/*antagonists & 
      inhibitors/pharmacology
MH  - Infusions, Intraventricular
MH  - Male
MH  - Memory/*drug effects
MH  - Memory Disorders/chemically induced/*drug therapy
MH  - Mice
MH  - Neuropeptides/administration & dosage/*pharmacology
MH  - Peptide Fragments/administration & dosage/*antagonists & inhibitors/pharmacology
MH  - Receptors, Neuropeptide/agonists
MH  - Recognition, Psychology/*drug effects
MH  - Scopolamine/administration & dosage/*antagonists & inhibitors/pharmacology
EDAT- 2013/03/05 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/03/05 06:00
PHST- 2012/09/06 00:00 [received]
PHST- 2013/01/24 00:00 [revised]
PHST- 2013/02/02 00:00 [accepted]
PHST- 2013/03/05 06:00 [entrez]
PHST- 2013/03/05 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
AID - S0028-3908(13)00044-0 [pii]
AID - 10.1016/j.neuropharm.2013.02.002 [doi]
PST - ppublish
SO  - Neuropharmacology. 2013 Jul;70:261-7. doi: 10.1016/j.neuropharm.2013.02.002. Epub 
      2013 Feb 21.